• Shou-Bao Wang
  • Xiu-Ying Yang
  • Guan-Hua DuEmail author


Anisodine was separated from the herbal medicine Anisodus tanguticus from Qinghai province, and its hydrobromide form was an originally created new drug in China. It competes with acetylcholine in the M cholinergic receptor to prevent acetylcholine from binding M cholinergic receptor, thus blocking the nerve impulse transmission and interfering with the physiological function based on the cholinergic neurotransmission. Anisodine has weaker intensity of action than atropine, as well as toxicity. Oral anisodine is absorbed rapidly and completely. At first, anisodine was mainly used in the treatment of various diseases of the central nervous system. The efficacy of anisodine for the treatment of cerebrovascular disease was validated from 1970 to 1975. Recently, compound anisodine injection based on a combination of procaine and anisodine hydrobromide showed a good effect for a variety of ischemic eye diseases induced by a variety of causes and other related eye diseases, especially superior to traditional therapies for ischemic lesions of the optic nerve, retina, and choroid. This drug has been widely used in China to promote the treatment for various eye diseases which achieved exciting results.


Anisodine M cholinergic receptor Compound anisodine injection Ischemic eye diseases 


  1. 1.
    Xie J, Wang L, Yongqi L, et al. Chemical structure of anisodine. Chin Sci Bull. 1975;10:52–3.Google Scholar
  2. 2.
    The First Pharmaceutical Factory of Chengdu. Production process of anisodine hydrobromide. Pharm Ind. 1975;5:12–5.Google Scholar
  3. 3.
    Weijian C. Pharmacological and clinical application of anisodine. Jiangsu Med J. 1976;2:50–2.CrossRefGoogle Scholar
  4. 4.
    Xie J, Jin Z, Chunzhen Z, et al. New progress in the synthesis of anisodine. J Chin Acad Med Sci. 1982;4(2):92–6.Google Scholar
  5. 5.
    Varma DR, Yue TL. Adrenoceptor blocking properties of atropine-like agents anisodamine and anisodine on brain and cardiovascular tissues of rats. Br J Pharmacol. 1986;87(3):587–94.CrossRefGoogle Scholar
  6. 6.
    Xiu RJ, Hammerschmidt DE, Coppo PA, et al. Anisodamine inhibits thromboxane synthesis, granulocyte aggregation, and platelet aggregation. A possible mechanism for its efficacy in bacteremic shock. J Am Med Assn. 1982;247:1458–60.CrossRefGoogle Scholar
  7. 7.
    Chao L, Lu N. Compound hydrobromide on the recovery of visual function in the control of glaucoma with intraocular pressure. J Clin Ophthalmol. 2002;10(3):246–7.Google Scholar
  8. 8.
    Juan P, Hu X, Gao D, et al. Clinical application of compound anisodine injection in ophthalmology. Int J Ophthalmol. 2007;7(4):1124–7.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2018

Authors and Affiliations

  1. 1.Beijing Key Laboratory of Drug Targets Identification and Drug Screening, National Centre for Pharmaceutical ScreeningInstitute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations